Results 171 to 180 of about 87,373 (338)

Biomarkers of Cellular Senescence in Type 2 Diabetes Mellitus

Aging Cell, EarlyView.
In cohorts of lean controls, obese participants without Type 2 Diabetes Mellitus (T2DM) and obese T2DM participants, we find that T‐cell expression of senescence biomarkers is altered only in the T2DM participants and not with obesity alone. Moreover, high T‐cell p16 expression in the T2DM participants is associated with impaired bone cortical indices.
Caroline Hoong, Joshua N. Farr, David G. Monroe, Thomas A. White, Elizabeth J. Atkinson, Amanda Tweed, Allyson K. Palmer, Nathan K. LeBrasseur, Jad G. Sfeir, Sundeep Khosla   +9 more
wiley   +1 more source

Reassessment of the relationship between M-protein decrement and survival in multiple myeloma [PDF]

, 1989
Martin Palmer, Andrew R. Belch, John Hanson, Larry W. Brox   +3 more
openalex   +1 more source

Can we identify individuals at risk to develop multiple myeloma? A machine learning‐based predictive model

British Journal of Haematology, EarlyView.
Individuals who may develop multiple myeloma within 5 years. Stage I (left) identifies patient and control groups and variables that differ between them. Stage II (middle) develops a complex SGBOOST model to predict future MM patients. Stage III (right) develops a simplified model.
Moshe Mittelman, Ariel Israel, Howard S. Oster, Michael Leshchinsky, Yatir Ben‐Shlomo, Eldad Kepten, Osnat Jarchowsky Dolberg, Ran Balicer, Galit Shaham   +8 more
wiley   +1 more source

Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro [PDF]

, 1988
Koji Iwato, Michio Kawano, Hideki Asaoku, Osamu Tanabe, Hideo Tanaka, Atsushi Kuramoto   +5 more
openalex   +1 more source

The progression of multiple myeloma is regulated by LILRB1 via the GATA2–SAGE1 pathway

British Journal of Haematology, EarlyView.
Summary Multiple myeloma (MM) is a haematological malignancy characterized by the clonal expansion of plasma cells within the bone marrow, thus resulting in the overproduction of monoclonal immunoglobulins. Despite the availability of various immunotherapeutic strategies, patient survival rates remain disappointingly low, thus underscoring the need for
Chiqi Chen, Xuanyi Zhou, Liyuan Cao, Wenqian Yang, Lietao Weng, Jin Yuan, Wen Zhou, Zhuo Yu, Junke Zheng   +8 more
wiley   +1 more source

MAFB: a key regulator of myeloid commitment involved in hematological diseases. [PDF]

Cell Death Discov
Ventura AB, Loconte T, Negri A, Viggiano L, Fiermonte G, Ciavarella S, Guarini A, Volpe G.   +7 more
europepmc   +1 more source

The circular dichroism of phosphocholine-specific mouse hybridoma and myeloma proteins: Unusual properties of the hybridoma protein 101.6g6 [PDF]

, 1985
N. Martin Young, Ross E. Williams, J L Claflin   +2 more
openalex   +1 more source

Polymorphisms in Necroptosis Pathway Genes: Novel Prognostic Markers for Multiple Myeloma Treatment Outcomes. [PDF]

Int J Mol Sci
Sokołowski M, Łacina P, Bogunia-Kubik K, Mazur G, Butrym A.   +4 more
europepmc   +1 more source

Thymine and guanine base specificity of human myeloma proteins with anti-DNA activity. [PDF]

, 1986
Moncef Zouali, B. David Stollar
openalex   +1 more source

Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma. [PDF]

Clin Exp Med
Sedlacek J.
europepmc   +1 more source